-
Prevalence and Patient Characteristics of Ectodermal Dysplasias in Denmark. JAMA Dermatol. (IF 10.9) Pub Date : 2024-03-13 Laura Krogh Herlin, Sigrun A J Schmidt, Xenia Buus Hermann, Kirsten Rønholt, Anette Bygum, Annette Schuster, Ulrikke Lei, Mette Mogensen, Gabrielle R Vinding, Malene Djursby, Hanne Hove, Jenny Blechingberg, Lise Graversen, Trine H Mogensen, Hans Gjørup, Sinéad M Langan, Mette Sommerlund
Ectodermal dysplasias constitute a group of rare genetic disorders of the skin and skin appendages with hypodontia, hypotrichosis, and hypohidrosis as cardinal features. There is a lack of population-based research into the epidemiology of ectodermal dysplasias.
-
Mal de Meleda. JAMA Dermatol. (IF 10.9) Pub Date : 2024-03-13 Pei-Yun Ho, Yi-Tsz Lin
This case report describes diffuse waxy palmoplantar hyperkeratosis in a symmetrically well-demarcated “gloves and socks” distribution with nail dystrophy.
-
Consent and Identifiability for Patient Images in Research, Education, and Image-Based Artificial Intelligence. JAMA Dermatol. (IF 10.9) Pub Date : 2024-03-13 Trina Salvador, Lilly Gu, Jennifer L Hay, Nicholas R Kurtansky, Ruth Masterson-Creber, Allan C Halpern, Veronica Rotemberg
This survey study reports the perspectives and preferences of US adults regarding use of photographs of their skin in medical research, education, and development of image-based artificial intelligence (AI).
-
Expert Recommendations on Use of Topical Therapeutics for Vitiligo in Pediatric, Adolescent, and Young Adult Patients. JAMA Dermatol. (IF 10.9) Pub Date : 2024-03-13 Yael Renert-Yuval, Khaled Ezzedine, Pearl Grimes, David Rosmarin, Lawrence F Eichenfield, Leslie Castelo-Soccio, Victor Huang, Seemal R Desai, Samantha Walsh, Jonathan I Silverberg, Amy S Paller, Michele Rodrigues, Mark Weingarten, Shanthi Narla, Jackie Gardner, Michael Siegel, Sidra Ibad, Nanette B Silverberg
Evidence-based recommendations for the treatment of vitiligo in pediatric, adolescent, and young adult patients in the US are needed.
-
Adjuvant Immunotherapy in Stage II Melanoma-Further Risk Stratification is Needed. JAMA Dermatol. (IF 10.9) Pub Date : 2024-03-13 Hannah Rashdan, Adewole Adamson, Yevgeniy R Semenov
This Viewpoint reviews the evidence for immune checkpoint inhibitor use in the adjuvant setting, discusses the individual and societal risks, benefits, and costs associated with immune checkpoint inhibitors, and highlights the need for more targeted patient selection approaches.
-
Current State of Dermatology Mobile Applications With Artificial Intelligence Features: A Scoping Review. JAMA Dermatol. (IF 10.9) Pub Date : 2024-03-07 Shannon Wongvibulsin, Matthew J Yan, Vartan Pahalyants, William Murphy, Roxana Daneshjou, Veronica Rotemberg
With advancements in mobile technology and artificial intelligence (AI) methods, there has been a substantial surge in the availability of direct-to-consumer mobile applications (apps) claiming to aid in the assessment and management of diverse skin conditions. Despite widespread patient downloads, these apps exhibit limited evidence supporting their efficacy.
-
Symptoms of Cognitive Impairment Among Children With Atopic Dermatitis. JAMA Dermatol. (IF 10.9) Pub Date : 2024-03-06 Emily Z Ma, Hannah R Chang, Sarah Radtke, Joy Wan
Previous studies suggest that atopic dermatitis (AD) is associated with cognitive impairment in children, but these studies have relied primarily on neurodevelopmental diagnoses (rather than symptoms) as proxy measures of cognitive function. It remains unknown if certain subpopulations of children with AD are at greater risk of cognitive impairment.
-
Erythematous Plaque Studded With Papules and Pustules in an Immunocompetent Patient. JAMA Dermatol. (IF 10.9) Pub Date : 2024-03-06 Ahmad B Shahin, Munir H Idriss, Julia S Lehman
A male patient was evaluated by the dermatology inpatient consult service after a 5-week history of a skin lesion on the right anterior thigh with intermittent itching and mild tenderness to palpation. What is your diagnosis?
-
Anatomic Subtype Differences in Extramammary Paget Disease: A Meta-Analysis. JAMA Dermatol. (IF 10.9) Pub Date : 2024-03-06 Nour Kibbi, Joshua L Owen, Brandon Worley, Jake X Wang, Vishnu Harikumar, Sumaira Z Aasi, Sunandana Chandra, Jennifer N Choi, Yasuhiro Fujisawa, Christos Iavazzo, John Y S Kim, Naomi Lawrence, Mario M Leitao, Allan B MacLean, Jeffrey S Ross, Anthony M Rossi, Sabah Servaes, Michael J Solomon, Murad Alam
Extramammary Paget disease (EMPD) is a rare, highly recurrent cutaneous malignant neoplasm of unclear origin. EMPD arises most commonly on the vulvar and penoscrotal skin. It is not presently known how anatomic subtype of EMPD affects disease presentation and management.
-
Immunohistochemistry for Diagnosing Melanoma in Older Adults. JAMA Dermatol. (IF 10.9) Pub Date : 2024-03-06 Kenechukwu Ojukwu, Megan M Eguchi, Adewole S Adamson, Kathleen F Kerr, Michael W Piepkorn, Stacey Murdoch, Raymond L Barnhill, David E Elder, Stevan R Knezevich, Joann G Elmore
Pathologic assessment to diagnose skin biopsies, especially for cutaneous melanoma, can be challenging, and immunohistochemistry (IHC) staining has the potential to aid decision-making. Currently, the temporal trends regarding the use of IHC for the examination of skin biopsies on a national level have not been described.
-
Spesolimab Response in a Girl With Acrodermatitis Continua of Hallopeau. JAMA Dermatol. (IF 10.9) Pub Date : 2024-02-28 Youcong Wang, Li Zhang, Jie Zheng, Xia Li, Lihong Chen
This case report summarizes the treatment of acrodermatitis continua of Hallopeau with spesolimab in a 9-year-old girl.
-
Incidence and Factors Associated With Second Primary Invasive Melanoma in Norway. JAMA Dermatol. (IF 10.9) Pub Date : 2024-02-28 Reza Ghiasvand, Adele C Green, Marit B Veierød, Trude E Robsahm
Patients diagnosed with a primary melanoma are at high risk of subsequent melanomas. Understanding the risk of second primary invasive melanoma and associated factors is crucial to optimize patient follow-up.
-
Patient-Reported Outcomes and Mortality in Cutaneous Chronic Graft-vs-Host Disease. JAMA Dermatol. (IF 10.9) Pub Date : 2024-02-28 Emily Baumrin, Daniel B Shin, Nandita Mitra, Joseph Pidala, Najla El Jurdi, Stephanie J Lee, Alison W Loren, Joel M Gelfand
Chronic graft-vs-host disease (GVHD) is associated with impaired quality of life and symptom burden. The independent association of skin involvement with patient-reported outcomes (PROs) and their utility as a clinical prognostic marker remain unknown. Identification of patients with cutaneous chronic GVHD and impaired PROs could assist in initial risk stratification and treatment selection.
-
Identifying Core Outcome Domains in Chronic Skin Disease Using the Best-Worst Scaling Method. JAMA Dermatol. (IF 10.9) Pub Date : 2024-02-21 Ali Shields, Frances K Barg, Wendy Smith Begolka, Kathy Sage, Kelly Druby, George C Gondo, David J Margolis, Andrea L Pusic, John S Barbieri
The use of patient-reported outcome measures (PROMs) potentially holds promise as an opportunity to improve outcomes and quality of care for patients with skin disease, but the routine use of PROMs remains limited. While the Patient-Reported Outcomes Measurement Information System (PROMIS) has several strengths and domains relevant to those with chronic skin disease, it is not clear which are most
-
Annular Erythematous Eruption in a Pediatric Patient. JAMA Dermatol. (IF 10.9) Pub Date : 2024-02-21 Samar Sheriff, Soon Bahrami, Courtney R Schadt
An 11-year-old girl presented in autumn with an asymptomatic rash on her arms, face, and legs of a 3-week duration. What is your diagnosis?
-
Use of Efficiency Frontiers to Align Prices and Clinical Benefits of Biologic Therapies for Plaque Psoriasis. JAMA Dermatol. (IF 10.9) Pub Date : 2024-02-21 Alexander C Egilman, Aaron S Kesselheim, Jerry Avorn, Adam J N Raymakers, Benjamin N Rome
The US lacks a systematic approach for aligning drug prices with clinical benefit, and traditional cost-effectiveness analysis (CEA) faces political obstacles. The efficiency frontier (EF) method offers policymakers an alternative approach.
-
Macrocheilia as an Atypical Clinical Presentation of Capillary Malformation-Arteriovenous Malformation Type 2. JAMA Dermatol. (IF 10.9) Pub Date : 2024-02-14 Roger Rovira-López, Luis A Pérez-Jurado, Ramon M Pujol
This case report describes a 53-year-old man with multiple erythematous macules and papules diffusely distributed on the frontal area, cheeks, eyelids, nose, and supralabial skin.
-
Deep Vein Thrombosis and Healing Outcomes in Patients With Pyoderma Gangrenosum. JAMA Dermatol. (IF 10.9) Pub Date : 2024-02-14 Hannah Zhao, Sidharth K Sengupta, Jonathan M Sisley, Olivia Haddadin, Hailey Pfeifer, Alex G Ortega-Loayza
This single-center prospective case-control study assessed the association between deep vein thrombosis and healing outcomes in patients with pyoderma gangrenosum.
-
Lived Experiences and Fear of Cancer Recurrence Among Survivors of Localized Cutaneous Melanoma. JAMA Dermatol. (IF 10.9) Pub Date : 2024-02-14 Ayisha N Mahama, Courtney N Haller, Jocelyn Labrada, Christie I Idiong, Alex B Haynes, Elizabeth A Jacobs, Joel Tsevat, Michael P Pignone, Adewole S Adamson
Most of the rapid increase in cutaneous melanoma incidence in the US has been localized disease that is treated surgically and is associated with high survival rates. However, little is known about the psychological well-being of survivors in the US.
-
Efficacy and Durability of Intravenous Ertapenem Therapy for Recalcitrant Hidradenitis Suppurativa. JAMA Dermatol. (IF 10.9) Pub Date : 2024-02-14 Avigdor Nosrati, Peter Y Ch'en, McCall E Torpey, Neda Shokrian, Gretchen Ball, Gabrielle Benesh, Tyler M Andriano, Tian Ran Zhu, Haley D Heibel, H Dean Hosgood, Kristina L Campton, Steven R Cohen
Hidradenitis suppurativa (HS) is a debilitating follicular skin disorder in which bacterial colonization is typical. Oral antibiotic efficacy can be unreliable; however, selective intravenous antibiotics, specifically ertapenem, may provide favorable clinical outcomes.
-
Clinical, Histologic, and Transcriptomic Evaluation of Sequential Fat Grafting for Morphea: A Nonrandomized Controlled Trial. JAMA Dermatol. (IF 10.9) Pub Date : 2024-02-07 Juzi Liu, Jing Wang, Qian Zhang, Feng Lu, Junrong Cai
Morphea is a rare disease of unknown etiology without satisfactory treatment for skin sclerosis and soft tissue atrophy.
-
Persistent Hyperkeratotic Plaques on a Man's Genitogluteal Area. JAMA Dermatol. (IF 10.9) Pub Date : 2024-02-07 Qian Zhang, Cheng-Cheng Liu, Jiu-Hong Li
A man in his 40s presented with a 10-year history of pruritic lesions on the scrotum and buttock. What is your diagnosis?
-
The Alopecia Areata Severity and Morbidity Index (ASAMI) Study: Results From a Global Expert Consensus Exercise on Determinants of Alopecia Areata Severity. JAMA Dermatol. (IF 10.9) Pub Date : 2024-02-07 Anthony Moussa, Michaela Bennett, Dmitri Wall, Nekma Meah, Katherine York, Laita Bokhari, Leila Asfour, Huw Rees, Leonardo Spagnol Abraham, Daniel Asz-Sigall, Fitnat Buket Basmanav, Wilma Bergfeld, Regina C Betz, Bevin Bhoyrul, Ulrike Blume-Peytavi, Valerie Callender, Vijaya Chitreddy, Andrea Combalia, George Cotsarelis, Brittany Craiglow, Rachita Dhurat, Jeff Donovan, Andrei Doroshkevich, Samantha
Current measures of alopecia areata (AA) severity, such as the Severity of Alopecia Tool score, do not adequately capture overall disease impact.
-
Federated Learning for Decentralized Artificial Intelligence in Melanoma Diagnostics. JAMA Dermatol. (IF 10.9) Pub Date : 2024-02-07 Sarah Haggenmüller, Max Schmitt, Eva Krieghoff-Henning, Achim Hekler, Roman C Maron, Christoph Wies, Jochen S Utikal, Friedegund Meier, Sarah Hobelsberger, Frank F Gellrich, Mildred Sergon, Axel Hauschild, Lars E French, Lucie Heinzerling, Justin G Schlager, Kamran Ghoreschi, Max Schlaak, Franz J Hilke, Gabriela Poch, Sören Korsing, Carola Berking, Markus V Heppt, Michael Erdmann, Sebastian Haferkamp
The development of artificial intelligence (AI)-based melanoma classifiers typically calls for large, centralized datasets, requiring hospitals to give away their patient data, which raises serious privacy concerns. To address this concern, decentralized federated learning has been proposed, where classifier development is distributed across hospitals.
-
Support Group Participation Among Patients With Alopecia Areata. JAMA Dermatol. (IF 10.9) Pub Date : 2024-02-07 Reneé Haughton, Samantha Herbert, Summer Meyer, Olivia Kam, Emanual Maverakis, Maija Kiuru
This cross-sectional study describes support group use and experience among patients with alopecia areata.
-
Estimated Spending on Beremagene Geperpavec for Dystrophic Epidermolysis Bullosa. JAMA Dermatol. (IF 10.9) Pub Date : 2024-01-31 Adam J N Raymakers, Aaron S Kesselheim, Arash Mostaghimi, William B Feldman
New gene therapies can offer substantial benefits to patients, particularly those with rare diseases who have few therapeutic options. In May 2023, the US Food and Drug Administration (FDA) approved the first topical gene therapy, beremagene geperpavec (B-VEC), for treating both autosomal recessive and autosomal dominant dystrophic epidermolysis bullosa (DEB). However, FDA approval was based on limited
-
Short-Term Cardiovascular Complications in Dermatology Patients Receiving JAK-STAT Inhibitors: A Meta-Analysis of Randomized Clinical Trials. JAMA Dermatol. (IF 10.9) Pub Date : 2024-01-31 Patrick A Ireland, Nicholas Jansson, Sascha K R Spencer, Jorja Braden, Deshan Sebaratnam
Evolving evidence suggests that patients receiving Janus kinase-signal transducer and activator of transcription inhibitors (JAK-STATi) may be at higher risk of major adverse cardiovascular events (MACE) and venous thromboembolism (VTE). Most existing literature has focused on indications that may confer a higher MACE and VTE risk than that among patients with isolated dermatological indications.
-
Prevalence of Pretreatment Testing Recommended for Patients With Chronic Inflammatory Skin Diseases. JAMA Dermatol. (IF 10.9) Pub Date : 2024-01-31 Maria C Schneeweiss, Denys Shay, Sophia Ly, Richard Wyss, Sebastian Schneeweiss, Robert J Glynn, Arash Mostaghimi
Laboratory testing for the presence of tuberculosis, hepatitis, and other conditions before starting most systemic immunomodulatory agents is recommended in patients with chronic inflammatory skin diseases (CISD) but current testing patterns in the US are unclear.
-
Perspectives on Full-Body Skin Examinations Among Sexual and Gender Minority Patients. JAMA Dermatol. (IF 10.9) Pub Date : 2024-01-31 Michelle Verghese, Jincong Q Freeman, Brian W Connor, Aniruddha Hazra, Andrew R Fisher, Adena E Rosenblatt
This survey study assesses full-body skin examination rates among sexual and gender minority patients and investigates their comfort with and reasons for discomfort during these examinations.
-
Favre-Racouchot Syndrome. JAMA Dermatol. (IF 10.9) Pub Date : 2024-01-31 Zhendong Wei, Fan Wang, Song Zheng
This case report describes multiple solitary open black comedones located bilaterally on the malar cheeks and temples as well as yellowish, smooth-surfaced papulonodular lesions in close association with the comedones.
-
Retrospective Case Series of Cocaine-Associated Plasma Cell Orificial Mucositis. JAMA Dermatol. (IF 10.9) Pub Date : 2024-01-24 Myriam Viedma-Martinez, Gonzalo Gallo-Pineda, Miguel Recio-Monescillo, David Jimenez-Gallo, Pablo Lopez-Sanz, Marta Drake-Monfort, Peru Urigoitia-Ugalde, Vicenta Martínez-Signes, David Llorca-Juan, Laura Fuertes-Vega, Elisa Ríos-Viñuela, Eduardo Escario-Travesedo, Juan José Ríos-Martín, Luis Requena-Caballero, Mario Linares-Barrios
Plasma cell orificial mucositis (PCOM) associated with cocaine use is an emerging, rare condition that has become a concern in Spain in recent years. Limited knowledge exists regarding this novel condition.
-
Annular Erythematous Plaques With Overlying Blisters in a Cluster of Jewels Pattern. JAMA Dermatol. (IF 10.9) Pub Date : 2024-01-24 Pablo López Sanz, Carlota Rodríguez de Vera Guardiola, Eduardo Escario Travesedo
A woman in her 80s presented with erythematous, nondesquamative, annular plaques in a cluster of jewels pattern on her wrists and legs. What is your diagnosis?
-
Patient-Reported Outcome Measures for Health-Related Quality of Life in Patients With Psoriasis: A Systematic Review. JAMA Dermatol. (IF 10.9) Pub Date : 2024-01-24 Lourdes M Pérez-Chada, Zachary H Hopkins, Deepak M W Balak, Sarem Rashid, Andrew Creadore, Brian Chu, Camila Villa, Michael J Woodbury, April W Armstrong, Vibeke Strand, Alice B Gottlieb, Joseph F Merola, John S Barbieri
Multiple patient-reported outcome measures (PROMs) for health-related quality of life (HRQL) exist for patients with psoriasis. Evidence for the content validity and other measurement properties of these PROMs is critical to determine which HRQL PROMs could be recommended for use.
-
Clinical Features and Outcomes of Black Patients with Melanoma. JAMA Dermatol. (IF 10.9) Pub Date : 2024-01-24 Sophia N Wix, Ariel B Brown, Meghan Heberton, Adewole S Adamson, Jennifer G Gill
Melanoma in Black individuals has an annual incidence of approximately 1 in 100 000 people. Most studies of melanoma in Black patients have used population databases, which lack important, precise clinical details.
-
Alopecia Areata. JAMA Dermatol. (IF 10.9) Pub Date : 2024-01-24 Ahana Gaurav, Brynner Eang, Arash Mostaghimi
This Patient Page describes the symptoms, diagnosis, and treatment of alopecia areata.
-
Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy: Follow-Up of the Ritux 3 Trial. JAMA Dermatol. (IF 10.9) Pub Date : 2024-01-24 Billal Tedbirt, Maud Maho-Vaillant, Estelle Houivet, Claire Mignard, Marie-Laure Golinski, Sébastien Calbo, Catherine Prost-Squarcioni, Bruno Labeille, Catherine Picard-Dahan, Guillaume Chaby, Marie-Aleth Richard, Emmanuelle Tancrede-Bohin, Sophie Duvert-Lehembre, Emmanuel Delaporte, Philippe Bernard, Frédéric Caux, Marina Alexandre, Philippe Musette, Saskia Ingen-Housz-Oro, Pierre Vabres, Gaëlle Quereux
The Ritux 3 trial demonstrated the short-term efficacy and safety of first-line treatment with rituximab compared with a standard corticosteroid regimen in pemphigus. No data on the long-term follow-up of patients who received rituximab as first line are available.
-
Erythrasma. JAMA Dermatol. (IF 10.9) Pub Date : 2024-01-17 Sharon Pan, Michael P Ryan, Ronald P Rapini
This case report describes well-demarcated brown plaques with overlying fine scale in the bilateral axillae, inframammary folds, and inguinal folds and widespread coral-red fluorescence.
-
Development and Validation of a Patient-Reported Outcome Measure to Assess Disease Control in Chronic Prurigo. JAMA Dermatol. (IF 10.9) Pub Date : 2024-01-17 Martin Metz, Claudia Zeidler, Tomasz Hawro, Manuel Pereira, Marcus Maurer, Hanna Bonnekoh, Karoline Krause, Thomas Pritchard, Shawn G Kwatra, Sonja Ständer, Karsten Weller
Chronic prurigo (CPG), including prurigo nodularis, is a difficult disease to treat and considerably affects patients' quality of life. Helping patients obtain control of CPG is a major treatment goal.
-
Causes and Clinical Presentation of Drug-Induced Dermatomyositis: A Systematic Review. JAMA Dermatol. (IF 10.9) Pub Date : 2024-01-10 Sahar Caravan, Christopher M Lopez, Jennifer E Yeh
While several medications are known to induce dermatomyositis (DM), most existing studies are case reports or small case series from a single institution. There is also limited information on DM induced by immune checkpoint inhibitors, which are increasingly used in oncologic therapy.
-
Segmental Skin Induration in a Boy. JAMA Dermatol. (IF 10.9) Pub Date : 2024-01-10 Yang Yang, Lan Zhang, Jiu-Hong Li
An 11-year-old boy presented with progressive unilateral skin hardening on his right thigh and buttock for 7 years. What is your diagnosis?
-
Treatment With Selumetinib for Café-au-Lait Macules and Plexiform Neurofibroma in Pediatric Patients With Neurofibromatosis Type 1. JAMA Dermatol. (IF 10.9) Pub Date : 2024-01-10 Ya-Xin Guo, He-Xiao Wang, Shan-Shan Wang, David Croitoru, Vincent Piguet, Xing-Hua Gao, Xue-Gang Xu
This case report describes 4 patients with a rare autosomal dominant multisystem disorder resulting from NF1 variants that leads to café-au-lait macules and neurofibromas.
-
Factors Affecting Treatment Selection Among Patients With Hidradenitis Suppurativa. JAMA Dermatol. (IF 10.9) Pub Date : 2024-01-10 Nicole Salame, Yacine N Sow, Meron R Siira, Amit Garg, Suephy C Chen, Rachel E Patzer, Dio Kavalieratos, Lauren A V Orenstein
Despite the US Food and Drug Administration's approval of adalimumab for the treatment of hidradenitis suppurativa (HS), prescription rates remain low, indicating a critical gap between evidence-based guidelines and clinical practice. Understanding the medical decision-making process that these patients use when considering biologic agents and other HS therapies may uncover opportunities for improved
-
Risk of Alopecia Areata After COVID-19. JAMA Dermatol. (IF 10.9) Pub Date : 2024-01-10 Jong-Seung Kim, Geon-Jong Lee, Cho-Yun Jeong, Sang-Woo Yeom, Kyung-Hwa Nam, Seok-Kweon Yun, Jin Park
This cohort study examines the incidence, prevalence, and risk of alopecia areata after COVID-19.
-
Papular Mucinosis. JAMA Dermatol. (IF 10.9) Pub Date : 2024-01-03 Alia Ahmadi, Ashlee Margheim, Courtney R Schadt
This case report describes erythematous patches on the face that involved the nasolabial folds, as well as numerous skin-colored homogenous waxy papules on the arms, neck, and trunk.
-
Clinical Characteristics of Erythema Nodosum and Associations With Chronicity and Recurrence. JAMA Dermatol. (IF 10.9) Pub Date : 2024-01-03 Jill T Shah, William Mark Richardson, Avrom S Caplan, Daniel R Mazori, Alisa N Femia
This cohort study characterizes the presentation, causes, treatment, and disease course of erythema nodosum, as well as identifies associations with chronicity and recurrence.
-
Genetic Risk Factors for Early-Onset Merkel Cell Carcinoma. JAMA Dermatol. (IF 10.9) Pub Date : 2024-01-03 Noreen Mohsin, Devin Hunt, Jia Yan, Austin J Jabbour, Paul Nghiem, Jaehyuk Choi, Yue Zhang, Alexandra F Freeman, Jenna R E Bergerson, Stefania Dell'Orso, Kristina Lachance, Rima Kulikauskas, Loren Collado, Wenjia Cao, Justin Lack, Morgan Similuk, Bryce A Seifert, Rajarshi Ghosh, Magdalena A Walkiewicz, Isaac Brownell
Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine skin cancer. Of the patients who develop MCC annually, only 4% are younger than 50 years.
-
Erythroderma in a Patient With Thymoma-Associated Myasthenia Gravis. JAMA Dermatol. (IF 10.9) Pub Date : 2024-01-03 Jia-Qi Chen, Wei Li, Sui-Qing Cai
A woman in her 30s with myasthenia gravis diagnosed at age 27 years presented to the emergency department with severe erythroderma over the past 2 months. What is your diagnosis?
-
Lived Experience of Acne and Acne Treatment in Transgender Patients. JAMA Dermatol. (IF 10.9) Pub Date : 2024-01-03 Sarah Gold, Meron Siira, Sigal Willner, Crescent Alcid, Suephy C Chen, Vin Tangpricha, Michael Goodman, Cam Escoffery, Ashli Owen-Smith, Howa Yeung
While acne is common in transgender and gender-diverse people and is associated with gender-affirming hormone therapy, little research has examined these factors and their impact in gender minority groups.
-
Melanoma Incidence Rates Among Non-Hispanic American Indian/Alaska Native Individuals, 1999-2019. JAMA Dermatol. (IF 10.9) Pub Date : 2023-12-27 Julie S Townsend, Stephanie C Melkonian, Melissa A Jim, Dawn M Holman, Melissa Buffalo, Anne K Julian
Non-Hispanic American Indian/Alaska Native people have the second highest incidence rate of invasive cutaneous melanoma in the US after non-Hispanic White people.
-
Ruxolitinib for Refractory PL-12 Antisynthetase Syndrome-Associated Angioedema-Like Panniculitis With Clonal T-Cell Receptor Gene Rearrangement. JAMA Dermatol. (IF 10.9) Pub Date : 2023-12-20 Srona Sengupta, Brandon Law, Rachel Sennett, Jaroslaw J Jedrych, Jemima Albayda, Jun K Kang
This case report describes a woman in her 30s who presented with a 3-year history of anti–PL-12 antisynthetase syndrome characterized by interstitial lung disease, arthritis, and myositis and was diagnosed with antisynthetase syndrome–associated panniculitis.
-
Meaningful Change Thresholds for the Psoriasis Symptoms and Signs Diary: A Secondary Analysis of a Randomized Clinical Trial. JAMA Dermatol. (IF 10.9) Pub Date : 2023-12-20 Kim A Papp, Kenneth Gordon, Bruce Strober, Joe Zhuo, Brandon Becker, Yichen Zhong, Jennifer L Beaumont, Tan P Pham, Renata Kisa, Andrew A Napoli, Subhashis Banerjee, April W Armstrong
Change from baseline score on the validated Psoriasis Symptoms and Signs Diary (PSSD) is a widely used, patient-reported end point in clinical trials for psoriasis. Meaningful score change thresholds anchored to patient-reported assessments have not been established in a clinical trial setting.
-
Adenopathy and an Extensive Skin Patch Overlying a Plasmacytoma Syndrome. JAMA Dermatol. (IF 10.9) Pub Date : 2023-12-20 Won Ji Song, Dong Hyo Kim, Je-Ho Mun
This case report describes a central cobblestone-like mass and bone lesion on the spinous process of the L3 vertebra underlying the skin mass.
-
Efficacy and Safety of PF-07038124 in Patients With Atopic Dermatitis and Plaque Psoriasis: A Randomized Clinical Trial. JAMA Dermatol. (IF 10.9) Pub Date : 2023-12-20 Lawrence F Eichenfield, Sanela Tarabar, Seth Forman, Alfonso García-Bello, Gang Feng, Gerald Fetterly, Ping Mahling, Elena Peeva, Michael S Vincent, Deepa E Chandra
Atopic dermatitis (AD) and plaque psoriasis are inflammatory skin diseases with unmet need for effective topical treatments with few application site reactions.
-
Innovation in Development of Dermatologic Drugs Approved by the US Food and Drug Administration Between 2012 and 2022. JAMA Dermatol. (IF 10.9) Pub Date : 2023-12-20 Samir Kamat, Benjamin Ungar, Aneesh Agarwal, Joy Wan, Joseph S Ross, Ravi Gupta
This cross-sectional study characterizes the frequency and degree of innovation of new dermatologic drugs approved by the US Food and Drug Administration (FDA) from 2012 to 2022.
-
Newborn Girl Presenting With Erythema and Blisters. JAMA Dermatol. (IF 10.9) Pub Date : 2023-12-13 Jiayue Wang, Jiaosheng Xu
A female child presents for 3-year follow-up with erythema, vesicles, and bullae present since birth and an increasing number of annular hyperkeratotic plaques and palmoplantar hyperkeratosis. What is your diagnosis?
-
The Problematic Legacy of Skin-Thickness Measurement in Race-Based Dermatology Research. JAMA Dermatol. (IF 10.9) Pub Date : 2023-12-13 Nakisa B Sadeghi, Adewole S Adamson
This Viewpoint presents an opportunity for dermatologists to think critically about how race has affected skin research.
-
Risk of Subsequent Vitiligo in Transplant Recipients With Comorbid Graft-vs-Host Disease. JAMA Dermatol. (IF 10.9) Pub Date : 2023-12-13 Chul Hwan Bang, Hae Eun Park, Yeong Ho Kim, Jin-Hyung Jung, Ji Hyun Lee, Young Min Park, Ju Hee Han
Vitiligo is a multifactorial, depigmenting skin disorder characterized by selective loss of melanocytes. Large-scale studies are lacking to determine the risk of vitiligo in transplant recipients with graft-vs-host disease (GVHD).
-
Treatment of Severe Palmoplantar Pustular Psoriasis With Bimekizumab. JAMA Dermatol. (IF 10.9) Pub Date : 2023-12-06 Thierry Passeron, Jean-Luc Perrot, Denis Jullien, Catherine Goujon, Mireille Ruer, Thierry Boyé, Axel P Villani, Nathalie Quiles Tsimaratos
Palmoplantar pustulosis (PPP) and palmoplantar plaque psoriasis with pustules remain challenging to treat. Studies suggest that an interleukin 17 or interleukin 36 loop acts synergistically in these diseases to induce palmoplantar pustules.
-
Successful Treatment of Recalcitrant Mpox Lesions With Intralesional Cidofovir in a Patient With HIV/AIDS. JAMA Dermatol. (IF 10.9) Pub Date : 2023-12-06 Connor R Buechler, Zachary Anderson, Sara A Kullberg, Daniel D Miller, Aileen Ahiskali, Ronald Schut, Sara A Hylwa
This case report describes a man in his 50s with HIV/AIDS who presented with widely scattered recalcitrant mpox lessions.
-
Oral Acitretin Plus Topical Triamcinolone vs Topical Triamcinolone Monotherapy in Patients With Symptomatic Oral Lichen Planus: A Randomized Clinical Trial. JAMA Dermatol. (IF 10.9) Pub Date : 2023-12-06 Keshavamurthy Vinay, Sheetanshu Kumar, Anubha Dev, Simone Cazzaniga, Luca Borradori, Vishal Thakur, Sunil Dogra
Symptomatic oral lichen planus (OLP) can be challenging to treat.